These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8847521)

  • 21. Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.
    Manservigi R; Grossi MP; Gualandri R; Balboni PG; Marchini A; Rotola A; Rimessi P; Di Luca D; Cassai E; Barbanti-Brodano G
    J Virol; 1990 Jan; 64(1):431-6. PubMed ID: 2152829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
    Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
    Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
    Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
    Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and protective effect of a DNA construct encoding certain neutralizing epitopes of herpes simplex virus type-1 glycoprotein B.
    Bamdad T; Roostaee MH; Sadeghizadeh M; Mahboudi F; Kazemnejad A; Soleimanjahi H
    Folia Biol (Praha); 2005; 51(4):109-13. PubMed ID: 16180546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
    Awasthi S; Belshe RB; Friedman HM
    J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1.
    Lowry PW; Koropchak CM; Choi CY; Mocarski ES; Kern ER; Kinchington PR; Arvin AM
    Antiviral Res; 1997 Feb; 33(3):187-200. PubMed ID: 9037375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K.
    Ghiasi H; Slanina S; Nesburn AB; Wechsler SL
    J Virol; 1994 Apr; 68(4):2347-54. PubMed ID: 8139020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.
    Simmons M; Murphy GS; Hayes CG
    Am J Trop Med Hyg; 2001 Aug; 65(2):159-61. PubMed ID: 11508393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.
    Kuklin N; Daheshia M; Karem K; Manickan E; Rouse BT
    J Virol; 1997 Apr; 71(4):3138-45. PubMed ID: 9060677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
    Rajcáni J; Sabó A; Mucha V; Kostál M; Compel P
    Acta Virol; 1995 Feb; 39(1):37-49. PubMed ID: 7572468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baculovirus-expressed glycoprotein G of herpes simplex virus type 1 partially protects vaccinated mice against lethal HSV-1 challenge.
    Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL
    Virology; 1992 Sep; 190(1):233-9. PubMed ID: 1529531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
    Stanfield BA; Stahl J; Chouljenko VN; Subramanian R; Charles AS; Saied AA; Walker JD; Kousoulas KG
    PLoS One; 2014; 9(10):e109890. PubMed ID: 25350288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-inducing properties of a prototype bivalent herpes simplex virus/enterotoxigenic Escherichia coli DNA vaccine.
    Lásaro MO; Alves AM; Botosso VF; Durigon EL; Ferreira LC
    FEMS Immunol Med Microbiol; 2003 Jan; 35(1):25-31. PubMed ID: 12589954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A vaccinia virus--herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome the HSV type 2 induced humoral immunosuppression and protect against vaginal challenge in BALB/c mice.
    Fleck M; Podlech J; Weise K; Falke D
    Med Microbiol Immunol; 1994 May; 183(2):87-94. PubMed ID: 7935163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.
    Lu Z; Brans R; Akhrameyeva NV; Murakami N; Xu X; Yao F
    J Invest Dermatol; 2009 May; 129(5):1174-84. PubMed ID: 19005489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
    Ghiasi H; Bahri S; Nesburn AB; Wechsler SL
    Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1352-60. PubMed ID: 7775113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
    J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y; Ghiasi H
    J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.